Warning! GuruFocus detected
5 Severe warning signs
with 9Y4.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Ryvu Therapeutics SA
NAICS : 325412
ISIN : PLSELVT00013
Description
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.39 | |||||
| Equity-to-Asset | 0.44 | |||||
| Debt-to-Equity | 0.41 | |||||
| Debt-to-EBITDA | -0.79 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.87 | |||||
| Beneish M-Score | -3.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 30.6 | |||||
| 3-Year EBITDA Growth Rate | -49.2 | |||||
| 3-Year EPS without NRI Growth Rate | -28.4 | |||||
| 3-Year FCF Growth Rate | -15 | |||||
| 3-Year Book Growth Rate | -1.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 9.86 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 46.98 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 12.94 | |||||
| 9-Day RSI | 18 | |||||
| 14-Day RSI | 22.41 | |||||
| 3-1 Month Momentum % | -40.87 | |||||
| 6-1 Month Momentum % | -46.74 | |||||
| 12-1 Month Momentum % | -51.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.03 | |||||
| Quick Ratio | 3.01 | |||||
| Cash Ratio | 2.51 | |||||
| Days Inventory | 45.56 | |||||
| Days Sales Outstanding | 75.47 | |||||
| Days Payable | 514.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8 | |||||
| Shareholder Yield % | -7.84 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 70.63 | |||||
| Operating Margin % | -164.93 | |||||
| Net Margin % | -163.69 | |||||
| FCF Margin % | -207.01 | |||||
| ROE % | -46.31 | |||||
| ROA % | -25.3 | |||||
| ROIC % | -63.43 | |||||
| 3-Year ROIIC % | -252.52 | |||||
| ROC (Joel Greenblatt) % | -133.98 | |||||
| ROCE % | -30.45 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shiller PE Ratio | 2.53 | |||||
| PS Ratio | 7.15 | |||||
| PB Ratio | 2.58 | |||||
| Price-to-Tangible-Book | 2.41 | |||||
| EV-to-EBIT | -2.58 | |||||
| EV-to-EBITDA | -2.88 | |||||
| EV-to-Revenue | 4.13 | |||||
| EV-to-FCF | -2.16 | |||||
| Price-to-GF-Value | 0.15 | |||||
| Price-to-Median-PS-Value | 0.34 | |||||
| Price-to-Net-Current-Asset-Value | 5.87 | |||||
| Price-to-Net-Cash | 20.85 | |||||
| Earnings Yield (Greenblatt) % | -38.75 | |||||
| FCF Yield % | -30.3 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ryvu Therapeutics SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 15.867 | ||
| EPS (TTM) (€) | -1.122 | ||
| Beta | 1.13 | ||
| 3-Year Sharpe Ratio | -0.23 | ||
| 3-Year Sortino Ratio | -0.36 | ||
| Volatility % | 36.17 | ||
| 14-Day RSI | 22.41 | ||
| 14-Day ATR (€) | 0.218893 | ||
| 20-Day SMA (€) | 5.9295 | ||
| 12-1 Month Momentum % | -51.56 | ||
| 52-Week Range (€) | 4.17 - 13.38 | ||
| Shares Outstanding (Mil) | 23.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ryvu Therapeutics SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ryvu Therapeutics SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ryvu Therapeutics SA Frequently Asked Questions
What is Ryvu Therapeutics SA(FRA:9Y4)'s stock price today?
The current price of FRA:9Y4 is €4.17. The 52 week high of FRA:9Y4 is €13.38 and 52 week low is €4.17.
When is next earnings date of Ryvu Therapeutics SA(FRA:9Y4)?
The next earnings date of Ryvu Therapeutics SA(FRA:9Y4) is 2025-03-22 Est..
Does Ryvu Therapeutics SA(FRA:9Y4) pay dividends? If so, how much?
Ryvu Therapeutics SA(FRA:9Y4) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers